Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07242469 | A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) | PHASE1 | RECRUITING | 52 | — | — | Dec 22, 2025 | Aug 28, 2026 | May 29, 2026 | 4 | United States |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs will be reported.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| Panel A MK-1403 + additive coformulation dose 1 | EXPERIMENTAL | Participants will receive MK-1403 + additive coformulation dose 1 orally once daily. |
| Panel A Placebo + additive coformulation dose 1 | PLACEBO_COMPARATOR | Participants will receive Placebo + additive coformulation dose 1 orally once daily. |
| Panel B MK-1403 + additive coformulation dose 2 | EXPERIMENTAL | Participants will receive MK-1403 + additive coformulation dose 2 orally once daily |
| Panel B Placebo + additive coformulation dose 2 | PLACEBO_COMPARATOR | Participants will receive Placebo + additive coformulation dose 2 orally once daily |
| Name | Type | Description |
|---|---|---|
| MK-1403 + additive coformulation | DRUG | MK-1403 + additive coformulation is a co-formulated product of MK-1403 administered orally. |
| Placebo + additive coformulation | DRUG | Placebo + additive coformulation is a co-formulated product of placebo administered orally. |
Inclusion Criteria: * Has a confirmed diagnosis of Type 2 diabetes mellitus (T2DM) * Has body mass index (BMI) between 18 and 40 kg/m\^2, inclusive Exclusion Criteria: * Has Type 1 diabetes mellitus or secondary types of diabetes * Has a history of congestive heart failure (New York Heart Associa...